These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 11147933)

  • 1. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
    Ramasubbu R; Ravindran A; Lapierre Y
    Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
    Francobandiera G
    Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study.
    Søholm B; Lublin H
    Acta Psychiatr Scand; 2003 May; 107(5):344-50. PubMed ID: 12752030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.
    Sareen J; Kirshner A; Lander M; Kjernisted KD; Eleff MK; Reiss JP
    J Affect Disord; 2004 Oct; 82(2):167-74. PubMed ID: 15488245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
    Sun TF; Lin PY; Wu CK
    Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].
    Weimer E; Braus DF; Cavus I; Thome J
    Fortschr Neurol Psychiatr; 2002 Apr; 70(4):210-7. PubMed ID: 11948436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study questions the benefit of the treatment. Aggressive Alzheimer patient -- a (not a) case for atypical neuroleptics?].
    Kurz A
    MMW Fortschr Med; 2006 Nov; 148(47):16. PubMed ID: 17168181
    [No Abstract]   [Full Text] [Related]  

  • 13. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
    Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
    J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
    de Haan L; Beuk N; Hoogenboom B; Dingemans P; Linszen D
    J Clin Psychiatry; 2002 Feb; 63(2):104-7. PubMed ID: 11874209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone-induced obsessive-compulsive symptoms: a series of six cases.
    Alevizos B; Lykouras L; Zervas IM; Christodoulou GN
    J Clin Psychopharmacol; 2002 Oct; 22(5):461-7. PubMed ID: 12352268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
    Miller DS; Yatham LN; Lam RW
    J Clin Psychiatry; 2001 Dec; 62(12):975-80. PubMed ID: 11780879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.
    Crocq MA; Leclercq P; Guillon MS; Bailey PE
    Eur Psychiatry; 2002 Sep; 17(5):296-7. PubMed ID: 12381502
    [No Abstract]   [Full Text] [Related]  

  • 20. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.
    Kim SW; Shin IS; Kim JM; Yang SJ; Hwang MY; Yoon JS
    J Clin Psychopharmacol; 2008 Jun; 28(3):349-52. PubMed ID: 18480697
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.